Darren Hodgson

Darren Hodgson

Company: AstraZeneca

Job title: Global Project Leader & Interim Site Head Translational Medicine Boston


Darren is interim site head of translational medicine (Boston) and project leader for the bladder cancer umbrella study IMED Oncology, AstraZeneca, having previously had positions in global medicine develop­ment, academia, biotechnology, and diagnostics sectors. Darren has over 10 years’ experience as leader or core member of a multi-functional global product team and has been responsible for strategy, internal and external assay development, clinical deployment, and regulatory representation for bio­markers used as primary, secondary, and exploratory objectives of clinical studies in all stages of drug development. Darren was the translational lead for Lynparza, which is AstraZeneca’s first in class PARP inhibitor approved in 2014. This was used for ovarian cancer indications in Europe and the US, which is defined by loss of function mutations in tumour suppressor genes. Darren is the author of numerous reviews, original patents and papers, journal editor and previously chairman of the Manchester Consumer Healthcare Ethics committee, and lecturer at the Universities of Manchester and Leeds.


Use of ctDNA for the Detection of Minimal Residual Disease in the Adjuvant Setting, Technical & Clinical Challenges: Are We There Yet? 8:30 am

• What do we need to test new cancer therapies in the adjuvant space? • What are the potential pitfalls?Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.